Pesquisas alternativas:
cancer ready » cancer real (Expandir a Pesquisa), cancer renal (Expandir a Pesquisa)
transl lung » transoral lung (Expandir a Pesquisa), transl dunja (Expandir a Pesquisa), cranial lung (Expandir a Pesquisa)
cancer res » cancer re (Expandir a Pesquisa), cancer real (Expandir a Pesquisa), cancer result (Expandir a Pesquisa)
A mostrar 1 - 18 resultados de 18 para a pesquisa 'transl lung ((cancer res) or (cancer ready))', tempo de pesquisa: 0.48seg Refinar resultados
Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials—are we in a new era?
Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
Prognostic markers in lung cancer: is it ready for prime time?

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?
The “liquid biopsy” in non-small cell lung cancer – not quite ready for prime time use

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Statistic and dosimetric criteria to assess the shift of the prescribed dose for lung radiotherapy plans when integrating point kernel models in medical physics: are we ready?
Adjuvant EGFR-TKIs-based therapy: are we ready?

EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?
International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa